Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Mini Review

Commercializing Biosimilar: Challenges, Strategies and Finding Path to Success

Prashant A Pandya*

Department of Program Management, Clinical Development, Navi Mumbai, India

*Corresponding Author:
Prashant A Pandya
Department of Program Management
Clinical Development, Navi Mumbai, India
Tel: +91-9967017172
E-mail: drpandya18@gmail.com

Received Date: August 02, 2017; Accepted Date: August 12, 2017; Published Date: August 21, 2017

Citation: Pandya PA (2017) Commercializing Biosimilar: Challenges, Strategies and Finding Path to Success. Clin Pharmacol Biopharm 6:173. doi: 10.4172/2167-065X.1000173

Copyright: © 2017 Pandya PA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Biosimilars and reference biologics have the same amino acid sequences. Differences in clinically inactive components are generally quite minor. Developments of Bio similar involve a series of complex decision and anyone of which have significant impact on Organization success. Early risk identification allows companies to put preventive measures in place to save development time and maximize return on investment. There are numerous development and regulatory constraints associated with biosimilar development affecting decision of commercialization. It is important to optimize commercialization strategies as regulations are still evolving hence it is vital for the companies to quickly modify biosimilar development strategies matching with the regulatory scenario.

Keywords

Top